

NEWS RELEASE



June 21, 2021

Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference

Kyoto, Japan, June 21, 2021 – Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Shigenobu Maekawa) announces a webcast during the PPMD 2021 Virtual Annual Conference held from June 23 to 26 (EDT). The presentation will feature new, long-term efficacy and safety data (interim analyses at 109 weeks) from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection.

The data presentation will be given by Paula Clemens, MD from the University of Pittsburgh School of Medicine and will be webcast live at 8 PM EDT on June 23. The webcast may be accessed at <https://ppmd2021.sched.com/venue/Live+Stream>. For more information including an archived version of the webcast, please visit the PPMD Virtual Annual Conference website (<https://www.parentprojectmd.org/get-involved/attend-events/annual-conference-2021-virtual/agenda/>).

About VILTEPSO

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. VILTEPSO received marketing authorization under an accelerated approval pathway in Japan in March 2020 and became commercially available in Japan in May of the same year. In the United States, it received accelerated approval from the US Food and Drug Administration (FDA) in August 2020 and has been marketed through NS Pharma, Inc.

About NS Pharma, Inc.

NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit <http://www.nspharma.com>. NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

FAX: +81-75-321-9128